TY - JOUR
T1 - Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints
AU - Hahn, RT
AU - Lawlor, MK
AU - TVARC Steering Committee
AU - Davidson, CJ
AU - Badhwar, V
AU - Sannino, A
AU - Spitzer, E
AU - Lurz, P
AU - Lindman, BR
AU - Topilsky, Y
AU - Baron, SJ
AU - Chadderdon, S
AU - Khalique, OK
AU - Tang, GHL
AU - Taramasso, M
AU - Grayburn, PA
AU - Badano, L
AU - Leipsic, J
AU - Lindenfeld, J
AU - Windecker, S
AU - Vemulapalli, S
AU - Redfors, B
AU - Alu, MC
AU - Cohen, DJ
AU - Rodes-Cabau, J
AU - Ailawadi, G
AU - Mack, M
AU - Ben-Yehuda, O
AU - Leon, MB
AU - Hausleiter, J
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Elsevier Inc on behalf of American College of Cardiology and The Society of Thoracic Surgeons and by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2023/11/14
Y1 - 2023/11/14
N2 - Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.
AB - Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.
UR - https://www.scopus.com/pages/publications/85176976166
U2 - 10.1093/eurheartj/ehad653
DO - 10.1093/eurheartj/ehad653
M3 - Article
C2 - 37793121
SN - 0195-668X
VL - 44
SP - 4508
EP - 4532
JO - European Heart Journal
JF - European Heart Journal
IS - 43
M1 - ehad653
ER -